HomeCompareAPPH vs ABBV

APPH vs ABBV: Dividend Comparison 2026

APPH yields 3003.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APPH wins by $459000609656.96M in total portfolio value
10 years
APPH
APPH
● Live price
3003.00%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$459000609657.07M
Annual income
$430,781,759,335,409,660.00
Full APPH calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — APPH vs ABBV

📍 APPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPPHABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APPH + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APPH pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APPH
Annual income on $10K today (after 15% tax)
$255,255.26/yr
After 10yr DRIP, annual income (after tax)
$366,164,495,435,098,200.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, APPH beats the other by $366,164,495,435,077,100.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APPH + ABBV for your $10,000?

APPH: 50%ABBV: 50%
100% ABBV50/50100% APPH
Portfolio after 10yr
$229500304828.58M
Annual income
$215,390,879,667,717,220.00/yr
Blended yield
93.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

APPH
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Price Target
$9.00
+13413.5% upside vs current
Range: $9.00 — $9.00
Altman Z
-1.7
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APPH buys
0
ABBV buys
0
No recent congressional trades found for APPH or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPPHABBV
Forward yield3003.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$459000609657.07M$102.3K
Annual income after 10y$430,781,759,335,409,660.00$24,771.77
Total dividends collected$457049700656.45M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$9.00$256.15

Year-by-year: APPH vs ABBV ($10,000, DRIP)

YearAPPH PortfolioAPPH Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$311,000$300,300.30$11,550$430.00+$299.4KAPPH
2$9,061,133$8,728,362.95$13,472$627.96+$9.05MAPPH
3$247,363,422$237,668,009.67$15,906$926.08+$247.35MAPPH
4$6,328,409,685$6,063,730,823.37$19,071$1,382.55+$6328.39MAPPH
5$151,753,784,210$144,982,385,847.26$23,302$2,095.81+$151753.76MAPPH
6$3,411,576,273,621$3,249,199,724,515.96$29,150$3,237.93+$3411576.24MAPPH
7$71,916,972,825,518$68,266,586,212,743.15$37,536$5,121.41+$71916972.79MAPPH
8$1,421,884,382,070,821$1,344,933,221,147,517.00$50,079$8,338.38+$1421884382.02MAPPH
9$26,372,757,309,958,452$24,851,341,021,142,676.00$69,753$14,065.80+$26372757309.89MAPPH
10$459,000,609,657,065,200$430,781,759,335,409,660.00$102,337$24,771.77+$459000609656.96MAPPH

APPH vs ABBV: Complete Analysis 2026

APPHStock

AppHarvest, Inc., an applied agricultural technology company, develops and operates indoor farms to grow non-GMO produce free of chemical pesticide residues. Its products include tomatoes; and other fruits and vegetables, such as berries, peppers, cucumbers, and salad greens. The company was incorporated in 2018 and is based in Morehead, Kentucky.

Full APPH Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this APPH vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APPH vs SCHDAPPH vs JEPIAPPH vs OAPPH vs KOAPPH vs MAINAPPH vs JNJAPPH vs MRKAPPH vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.